This phase III trial is evaluating bortezomib (a chemotherapy drug) and sorafenib tosylate (another type of drug) for the treatment of newly diagnosed Acute Myeloid Leukaemia (AML).
This trial is treating patients with Acute Myeloid Leukaemia.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have been diagnosed with cancer, but have not received any treatment.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
- NCI-2011-02670, COG-AAML1031, CDR0000701850, AAML1031, U10CA098543
A Phase III Randomized Trial for Patients With de Novo AML Using Bortezomib and Sorafenib for Patients With High Allelic Ratio FLT3/ITD
Other Non-Commercial Sponsor
National Cancer Institute (NCI)
This randomized phase III trial studies how well bortezomib and sorafenib tosylate work in treating patients with newly diagnosed acute myeloid leukemia. Bortezomib and sorafenib tosylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving bortezomib and sorafenib tosylate together with combination chemotherapy may be an effective treatment for acute myeloid leukemia
**A karyotypic abnormality characteristic of de novo AML (t(8;21)(q22;q22), inv(16)(p13q22) or t(16;16)(p13;q22) or 11q23 abnormalities)**
Not Recruiting Hospitals Read More